67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma

Journal of Nuclear Medicine

Volumn 40, Issue 2, 1999, Pages 302-310

  DeNardo, Sally J ^a   DeNardo, Gerald L ^b   Kukis, David L ^b   Shen, Sui ^b   Kroger, Linda A ^b   Denardo, Diane A ^b   Goldstein, Desiree S ^b   Mirick, Gary R ^b   Salako, Qansy ^b   Mausner, Leonard F ^b   Srivastava, Suresh C ^b   Meares, Claude F ^b  

^a Molecular Cancer Institute   (United States)

^b NONE

Author keywords

67Cu; Lymphoma; Pharmacokinetics; Radiation dosimetry; Radioimmunotherapy

Indexed keywords

COPPER 67; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; COPPER;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DOSIMETRY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; TREATMENT OUTCOME; IMMUNOLOGY; LYMPHOCYTE; MIDDLE AGED; RADIOIMMUNOTHERAPY; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COPPER RADIOISOTOPES; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY;

EID: 0032588605     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. DeNardo SJ, DeNardo GL, O'Grady LF. et al. Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers. 1987;2:49-53.
2. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
3. 131I-B1 (anti-CD20) antibody therapy with aulologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
4. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
5. Parker BA, Vassos AB, Halpern SE, et al. Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody. Cancer Res. 1990;50:1022-1028.
6. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991;9:548-564.
7. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
8. Vriesendorp HM, Herpst JM, Germack MA, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol. 1991;9:918-928.
9. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9:478-490.
10. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer. 1994;73:1425-1432.
11. 131I-Lym-1. Cancer Res. 1990;50(suppl):1014-1016.
12. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Cancer. 1997;80(suppl): 2706-2711.
13. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys. 1993;20:503-509.
14. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB, Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer. 1994;73(suppl):787-793.
15. DeNardo GL, DeNardo SJ. Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: Burchiel SW, Rhodes BA, eds. Radioimmunoimaging and Radioimmunotheraphy. New York, NY: Elsevier Science; 1983;41-62.
16. Jungerman JA, Yu KH, Zanelli CI. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. Int J Appl Radiat Isot. 1984;35:883-888.
17. Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr. 1996;63:797S-811S.
18. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem. 1985;148:249-253.
19. Kukis DL, Diril H, Greiner DP, et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer. 1994;73(suppl):779-786.
20. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res. 1995;55:878-884.
21. 62Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res. 1997;3:71-79.
22. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother. 1996;43:26-30.
23. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with inimunodiagnostic and immunotherapeutic potential. Cancer Res. 1987;47:830-840.
24. Hu E, Epstein AL, Naeve GS, et al. A phase Ia clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol. 1989;7:155-166.
25. DeNardo GL, DeNardo SJ, Meares CF, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and patients with lymphoma. Antibody Immunoconj Radiophar. 1991;4:777-785.
26. DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ. Antibody responses to macrocycles in lymphoma. J Nucl Med. 1996;37:451-456.
27. Erwin WD, Groch MW, Macey DJ, DeNardo GL, DeNardo SJ, Shen S. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol. 1996;23:525-532.
28. Shen S, DeNardo GL, DeNardo SJ, et al. Dosimetric evaluation of Cu-64 in Cu-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Mett. 1996;37:146-150.
29. Shen S, DeNardo GL, DeNardo SJ, Yuan A, DeNardo DA, Lamborn KR. Reproducibility of operator processing for radiation dosimetry. Nucl Med Biol. 1997;24:77-83.
30. Loevinger R, Berman M. A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides. MIRD Pamphlet no. I. New York. NY: Society of Nuclear Medicine: 1976:1-10.
31. Coffey JL, Watson EE. Calculating dose from remaining body activity: a comparison of two methods. Med Phys. 1979;6:307-308
32. Snyder WS, Ford MR, Warner GG. "S" Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet no. II. New York, NY: Society of Nuclear Medicine; 1975:82-83.
33. Shen S, DeNardo GL, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer. 1997;80(suppl):2553-2558.
34. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun. 1993;14:587-595.
35. Dillman LT, Von der Lage F. Radionuclide Decay Schemes and Nuclear Parameters for Use in Radiation-Dose Estimation, Part 2. MIRD Pamphlet no. 6. New York, NY: Society of Nuclear Medicine; 1970:5-32.
36. Lim S-M, DeNardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997;38:1374-1378.
37. Brodsky A. CRC Handbook of Radiation Measurements and Protection, Section A, vol. II: Biological and Mathematical Information. Boca Raton, FL: CRC Press; 1982:148-150.
38. DeNardo SJ, DeNardo GL. Tumor therapy with radioactive labeled antitumor antibodies. In: Moloy PJ, Nicolson G, eds. Cellular Oncology: New Approaches in Biology, Diagnosis and Treatment. New York, NY: Praeger Press; 1983: 282-292.
39. Release of Patients Administered Radioactive Materials. U.S. Nuclear Regulatory Commission Regulatory Guide 8.39. Washington, DC: U.S. Government Printing Office; 1977:1-5.
40. Bischof Delaloye A, Delaloye B, Buchegger F, et al. Comparison of copper-67-and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. J Nucl Med. 1997;38:847-853.
41. Wessels BW, Rogus RD. Radionuclide selection and model adsorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys. 1984;11:638-645.
42. Cole WC, DeNardo SJ, Meares CF, et al. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med 1987;28:83-90.
43. Stein R, Chen S, Haim S, Goldenberg DM. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer. 1997;80(suppl):2636-2641.
44. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako QA, Kukis DL. Yttrium-90/indium-111-DOTA-peptide-Chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res. 1997;17:1735-1744.
45. White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood. 1996;87: 3640-3649.
46. Dasgupta AK, Mausner LF, Srivastava SC. A new separation procedure for Cu-67 from proton irradiated Zn. J Appl Radiat Isot. 1991;42:371-376.
47. Srivaslava SC. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm. 1996;11: 43-50.